Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drug could improve learning in Down syndrome
The researchers discovered two interesting things when testing mice in the study. It was found that daily doses were required for several days before any effect was detected
The researchers discovered two interesting things when testing mice in the study. It was found that daily doses were required for several days before any effect was detected
This recommendation was granted by the Japanese Ministry of Health, Labour and Welfare and the approval is expected by mid-year. It was recommended that an early filing be
The trial did show that treatment with NovoSeven reduced intracerebral bleeding compared to placebo and there was an improvement in terms of functional independence and neurological impairment. However,
The new formulation is a modified release, once-daily formulation of Prograf, a leading immunosuppressive agent marketed around the world for prevention of organ rejection in kidney, liver or
Vyvanse is as a new ADHD medication designed to provide lower potential for abuse, in which d-amphetamine is covalently linked to l-lysine, a naturally occurring amino acid. The
This ongoing phase II study is designed to evaluate the non-inferiority of Gilead’s once-daily drug GS 9137, versus boosted comparator protease inhibitors. GS 9137 is an integrase inhibitor
The phase II study was assessing the optimal starting dose of Cera in anaemic patients with non-small cell lung cancer receiving first line chemotherapy. However, Roche said treatment
Switzerland-based Novartis said the EU submission for Focetria was considered a “mock-up” since it lays the groundwork for a more rapid approval and availability of a specific vaccine
Pfizer added that once each country updates its labeling, Celebrex will be the first oral selective COX-2 inhibitor available in Europe to treat this form of arthritis. Pfizer
Japan’s Astellas Pharma has a US patent on Flomax, which is used for the treatment of benign prostatic hyperplasia, until October 27, 2009. Astellas, and Boehringer Ingelheim of